BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//IAS-USA//NONSGML PDA Calendar Version 1.0//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:d90d658286fc64ddabff6942746743fa
ORGANIZER:registration@iasusa.org
DTSTAMP:20261026T124041Z
LOCATION:
SUMMARY:Optimizing Antiviral Outcomes Through Clinical Pharmacology
DESCRIPTION:[vc_row][vc_column][vc_column_text]\n\nOverview\n\nAssessment of Needs\nSeveral new antiviral drugs have become available in recent years including therapies for SARS-CoV2 and long-acting agents for HIV prevention and treatment. This webinar will compare and contrast the clinical pharmacology and concentration-effect associations for contemporary antivirals. Modern analytical approaches to define antiviral pharmacokinetic-dynamic relationships will also be discussed.\nLearning Objectives\nAt the end of this webinar\, participants will be able to:\n\n 	Define key clinical pharmacology concepts for antiviral drugs\n 	Compare and contrast the clinical pharmacology and concentration-effect associations for contemporary antivirals\n 	Describe modern analytical approaches to define pharmacokinetic-dynamic relationships\n\nRegistration\nWho Should Attend\nThis webinar is designed for clinical decision makers who are actively involved in HIV care and research\, including physicians\, physician assistants\, nursing professionals\, pharmacists\, and other health care professionals.\n\nIndividual registration is required in order to receive CME credit or a certificate of participation.\n\nRegistration closes on June 21\, 2022\, 9:00 AM (PT).\n\nCertificates will be available after the completion of the evaluation and claim form.\n\nFor more information or questions\, please contact the registration department at registration@iasusa.org or 415-544-9400.\nConflicts of Interest\nIn the interest of maintaining the independence of its continuing medical education (CME) activities\, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg\, faculty\, Scientific Leadership Board\, Governance Board\, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  \n\nThe Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as "those whose primary business is producing\, marketing\, selling\, re-selling\, or distributing healthcare products used by or on patients.” \n\nIAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.\n\n\nPresenter\n\nDr Kiser has received research funding paid to her institution from Gilead Sciences\, Inc.\, and ViiV Healthcare. (Updated 6/21/22)\n\n\nModerator\n\nDr Flexner has served as a consultant to Cipla Pharmaceuticals\, Janssen Pharmaceuticals\, Merck &amp\; Co\, Inc\, Mylan Pharmaceuticals\, and ViiV Healthcare\, and received research grant support paid to his institution from Gilead Sciences\, Inc. (Updated 6/21/22)\n\n\nPlanner/Reviewer\n\nPlanner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 6/21/22)\nPlanner/Reviewer 2 has no relevant financial relationships with ineligible companies to disclose. (Updated 6/21/22)\n\n\n\n\n\n\nCME Credits\nThe International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.\n\nThe IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\nABIM MOC Points\nSuccessful completion of this CME activity\, which includes participation in the evaluation component\, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA\, the CME activity provider\, will submit your participant information (eg\, name\, date of birth\, activity credits earned\, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.\nNursing Credits\nEducational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association\, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 1.25 hours of continuing nursing education.\n\nEducational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692)\, the state of Florida and the District of Columbia.\nPharmacy Credits\n Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.   Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event.  Please know that if accurate e-Profile information is not provided within 60 days of the event\, credit cannot be claimed after that time.  The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.\nUAN  #0761-9999-22-336-L01-P\nGrant Support\n\n\nThis activity is part of the IAS–USA national educational effort that is funded\, in part\, by charitable contributions from ineligible companies. Per IAS–USA policy\, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity\, including its content\, development\, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.\n\nPLATINUM SUPPORTERS\n\nGilead Sciences\, Inc.\nMerck &amp\; Co\, Inc.\nViiV Healthcare\n\nSILVER SUPPORTER\n\nJanssen Therapeutics\n\nBRONZE SUPPORTER\n\nTheratechnologies\, Inc.\n\n&nbsp\;\n\n\nFrequently Asked Questions\nView our list of FAQs about attending a webinar.\n\nFurther Questions?\nPlease contact the registration department at registration@iasusa.org or 415-544-9400.\n\n\n\n[/vc_column_text][/vc_column][/vc_row]
STATUS:CONFIRMED
CATEGORIES:Webinars
URL;VALUE=URI:https://www.iasusa.org/events/webinar-2022-kiser/
DTSTART:20220621T170000Z
DTEND:20220621T181500Z
END:VEVENT
END:VCALENDAR